Literature DB >> 14499860

Characterisation of the Na, K pump current in atrial cells from patients with and without chronic atrial fibrillation.

Antony J Workman1, Kathleen A Kane, Andrew C Rankin.   

Abstract

OBJECTIVE: To assess the contribution of the Na, K pump current (I(p)) to the action potential duration (APD) and effective refractory period (ERP) in human atrial cells, and to investigate whether I(p) contributes to the changes in APD and ERP associated with chronic atrial fibrillation (AF).
METHODS: Action potentials and ion currents were recorded by whole-cell patch clamp in atrial myocytes isolated from consenting patients undergoing cardiac surgery, who were in sinus rhythm (SR) or AF (>3 months).
RESULTS: In cells from patients in SR, the I(p) blocker, ouabain (10 microM) significantly depolarised the membrane potential, V(m), from -80+/-2 (mean+/-S.E.) to -73+/-2 mV, and lengthened both the APD (174+/-17 vs. 197+/-23 ms at 90% repolarisation) and ERP (198+/-22 vs. 266+/-14 ms; P<0.05 for each, Student's t-test, n=7 cells, 5 patients). With an elevated pipette [Na(+)] of 30 mM, I(p) was measured by increasing extracellular [K(+)] ([K(+)](o)) from 0 to 5.4 mM. This produced an outward shift in holding current at -40 mV, abolished by 10 microM ouabain. K(+)- and ouabain-sensitive current densities were similar, at 0.99+/-0.13 and 1.12+/-0.11 pA/pF, respectively (P>0.05; n=9 cells), confirming the K(+)-induced current as I(p). I(p) increased linearly with increasing V(m) between -120 and +60 mV (n=25 cells). Stepwise increments in [K(+)](o) (between 0 and 10 mM) increased I(p) in a concentration-dependent manner (maximum response, E(max)=1.19+/-0.09 pA/pF; EC(50)=1.71+/-0.15 mM; n=27 cells, 9 patients). In cells from patients in AF, the sensitivity of I(p) to both V(m) and [K(+)](o) (E(max)=1.02+/-0.05 pA/pF, EC(50)=1.54+/-0.11 mM; n=44 cells, 9 patients) was not significantly different from that in cells from patients in SR. Within the group of patients in AF, long-term digoxin therapy (n=5 patients) was associated with a small, but significant, reduction in E(max) (0.92+/-0.07 pA/pF) and EC(50) (1.35+/-0.15 mM) compared with non-treatment (E(max)=1.13+/-0.08 pA/pF, EC(50)=1.76+/-0.14 mM; P<0.05 for each, n=4 patients). In cells from non-digoxin-treated patients in AF, the voltage- and [K(+)](o)-sensitivity (E(max) and EC(50)) were similar to those in cells from patients in SR.
CONCLUSIONS: The Na, K pump current contributes to the human atrial cell V(m), action potential shape and ERP. However, the similarity in I(p) sensitivity to both [K(+)](o) and V(m) between atrial cells from patients with and without chronic AF indicates that I(p) is not involved in AF-induced electrophysiological remodelling in patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14499860     DOI: 10.1016/s0008-6363(03)00466-8

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  20 in total

Review 1.  Ion Channels in the Heart.

Authors:  Daniel C Bartos; Eleonora Grandi; Crystal M Ripplinger
Journal:  Compr Physiol       Date:  2015-07-01       Impact factor: 9.090

2.  Repolarization alternans reveals vulnerability to human atrial fibrillation.

Authors:  Sanjiv M Narayan; Michael R Franz; Paul Clopton; Etienne J Pruvot; David E Krummen
Journal:  Circulation       Date:  2011-06-06       Impact factor: 29.690

3.  Human atrial action potential and Ca2+ model: sinus rhythm and chronic atrial fibrillation.

Authors:  Eleonora Grandi; Sandeep V Pandit; Niels Voigt; Antony J Workman; Dobromir Dobrev; José Jalife; Donald M Bers
Journal:  Circ Res       Date:  2011-09-15       Impact factor: 17.367

Review 4.  Altered Excitation-Contraction Coupling in Human Chronic Atrial Fibrillation.

Authors:  Eleonora Grandi; Antony J Workman; Sandeep V Pandit
Journal:  J Atr Fibrillation       Date:  2012-04-14

Review 5.  Mechanisms of termination and prevention of atrial fibrillation by drug therapy.

Authors:  A J Workman; G L Smith; A C Rankin
Journal:  Pharmacol Ther       Date:  2011-02-18       Impact factor: 12.310

Review 6.  Cardiac adrenergic control and atrial fibrillation.

Authors:  Antony J Workman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-12-04       Impact factor: 3.000

7.  Prevention of atrial fibrillation: report from a national heart, lung, and blood institute workshop.

Authors:  Emelia J Benjamin; Peng-Sheng Chen; Diane E Bild; Alice M Mascette; Christine M Albert; Alvaro Alonso; Hugh Calkins; Stuart J Connolly; Anne B Curtis; Dawood Darbar; Patrick T Ellinor; Alan S Go; Nora F Goldschlager; Susan R Heckbert; José Jalife; Charles R Kerr; Daniel Levy; Donald M Lloyd-Jones; Barry M Massie; Stanley Nattel; Jeffrey E Olgin; Douglas L Packer; Sunny S Po; Teresa S M Tsang; David R Van Wagoner; Albert L Waldo; D George Wyse
Journal:  Circulation       Date:  2009-02-03       Impact factor: 29.690

Review 8.  Anti-arrhythmic strategies for atrial fibrillation: The role of computational modeling in discovery, development, and optimization.

Authors:  Eleonora Grandi; Mary M Maleckar
Journal:  Pharmacol Ther       Date:  2016-09-06       Impact factor: 12.310

9.  Repolarization and activation restitution near human pulmonary veins and atrial fibrillation initiation: a mechanism for the initiation of atrial fibrillation by premature beats.

Authors:  Sanjiv M Narayan; Dhruv Kazi; David E Krummen; Wouter-Jan Rappel
Journal:  J Am Coll Cardiol       Date:  2008-10-07       Impact factor: 24.094

10.  Cellular bases for human atrial fibrillation.

Authors:  Antony J Workman; Kathleen A Kane; Andrew C Rankin
Journal:  Heart Rhythm       Date:  2008-01-17       Impact factor: 6.343

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.